CGEN-15022 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen.
CGEN-15022 is expressed in numerous types of epithelial cancers, such as liver, colorectal, lung and ovarian cancers.
Studies using a recombinant fusion protein containing the extracellular domain of CGEN-15022 showed it is capable of inhibiting T cell activity. Beneficial effects were also observed in animal models of autoimmune animal diseases.
In August 2013, Compugen signed a research and discovery collaboration and license agreement with Bayer HealthCare for the development and commercialization of antibody-based therapeutics for cancer immunotherapy against CGEN-15022.